DIAGNOS Successfully Completes Private Placement
Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) has effectively concluded a non-brokered private placement, initially announced recently. This strategic move resulted in the issuance of 10 units, each priced at $10,000, attracting a total of $100,000 in gross proceeds.
Structure of the Private Placement
Details of Each Unit
Notably, each unit consists of one unsecured convertible debenture and stock warrants. The debentures, valued at $10,000 each, have a 12-month term ending the following year and carry an interest rate of 10% payable every six months. Shareholders have the option to convert these debentures into common shares at a price of $0.28 each during the term.
Additionally, each warrant allows the holder to purchase a common share at $0.40 anytime during the same period.
Intended Use of Funds
Funds raised from this private placement are earmarked primarily for product development and the commercialization of AI-driven screening services. Further allocations include general administrative expenses, highlighting the corporation's commitment to enhancing its operational capabilities.
Director Participation and Compliance
Intriguingly, the subscription of these units was made by one of the corporation's directors, classified as a related party under relevant laws. The transaction has received board approval following thorough evaluation to confirm that it aligns with the interests of DIAGNOS and its shareholders. Importantly, the participation of this director does not exceed 25% of the corporation's market capitalization, which allows the transaction to qualify for certain exemptions.
Regulatory Considerations
All securities issued through this private placement are subject to a statutory hold period, concluding in early January of the following year. The entire transaction will also require completion of all necessary approvals, including from the TSX Venture Exchange.
About DIAGNOS
DIAGNOS is a publicly traded corporation focused on the early detection of critical health issues, especially concerning eye-related conditions. By employing advanced Artificial Intelligence technology, the company strives to provide healthcare professionals with improved diagnostic tools, thereby enhancing patient outcomes globally.
For further information, please visit the official DIAGNOS website for updates and insights.
Frequently Asked Questions
What is the purpose of the private placement by DIAGNOS?
The fund raised will support product development, commercialization of AI-based services, and cover general expenses.
Who is participating in the private placement?
One director of DIAGNOS has subscribed to the units, considered a related party in the context of the placement.
What are the terms of the convertible debentures?
The debentures have a 12-month term, an interest rate of 10%, and can be converted into common shares at $0.28 each.
When does the statutory hold period end?
The hold period for the securities issued in the private placement ends in early January of the following year.
What is DIAGNOS's main service focus?
DIAGNOS focuses on early detection of eye-related health problems through advanced AI technology to improve diagnostic accuracy.
